Tivozanib (AV-951): Potent, Selective VEGFR Inhibitor for Oncology Research

Executive Summary: Tivozanib (AV-951) is a second-generation tyrosine kinase inhibitor (TKI) with picomolar potency against VEGFR-2 (IC50 = 160 pM), minimal off-target activity, and demonstrated antitumor efficacy in renal cell carcinoma (RCC) models and clinical trials (APExBIO). It is a quinoline-urea derivative, orally bioavailable, and typically administered at 1.5 mg once daily in RCC patient protocols. Tivozanib outperforms first-generation TKIs (e.g., sunitinib, sorafenib, pazopanib) in VEGFR-2 inhibition while preserving a favorable safety profile (Schwartz 2022). Its solubility profile, recommended storage (-20°C), and use in 10 μM cellular assays for 48 hours are critical for laboratory reproducibility. Combination with EGFR-directed therapies yields synergistic effects in ovarian carcinoma models.

Biological Rationale

Angiogenesis is essential for tumor growth and metastasis. Vascular endothelial growth factor (VEGF) signaling via VEGFR-1, VEGFR-2, and VEGFR-3 is a central driver of angiogenic processes in solid tumors (Schwartz 2022). Inhibiting VEGF pathways reduces neovascularization, starving tumors of nutrients and oxygen. Tivozanib (AV-951) was engineered to selectively block VEGFR signaling, addressing the need for potent, specific, and clinically effective anti-angiogenic agents. Compared to earlier TKIs, Tivozanib provides higher selectivity, reducing off-target toxicities and enhancing therapeutic index.

Mechanism of Action of Tivozanib (AV-951)

Tivozanib is a quinoline-urea small molecule that binds the ATP-binding site of VEGFR-1, VEGFR-2, and VEGFR-3, inhibiting their tyrosine kinase activity. The compound exhibits an IC50 of 160 pM against VEGFR-2, reflecting extremely high potency. Tivozanib also inhibits VEGFR-1 and VEGFR-3 in the low nanomolar range, with minimal inhibition of c-KIT and PDGFRβ except at higher concentrations. This selectivity reduces off-target effects. In cell-based assays, Tivozanib suppresses VEGFR phosphorylation, impeding downstream signaling required for angiogenesis and tumor progression. The result is reduced endothelial cell proliferation, migration, and new vessel formation (Schwartz 2022, UMassChan).

Evidence & Benchmarks

• Tivozanib achieves picomolar inhibition of VEGFR-2 kinase activity (IC50 = 160 pM), exceeding the potency of sunitinib, sorafenib, and pazopanib (Schwartz 2022).
• In RCC xenograft models, Tivozanib demonstrates significant tumor growth suppression compared to vehicle controls (Schwartz 2022).
• Clinically, Tivozanib (1.5 mg orally, once daily for 3 weeks on/1 week off) achieved a median progression-free survival (PFS) of 12.7 months in phase III RCC trials, a leading outcome among VEGFR inhibitors (Schwartz 2022).
• Tivozanib shows low off-target activity: c-KIT and PDGFRβ are only inhibited at nanomolar concentrations, reducing the risk of adverse effects (Schwartz 2022).
• Combination with EGFR inhibitors in vitro results in synergistic cell growth inhibition and apoptosis in ovarian carcinoma cell lines (Schwartz 2022).
• Tivozanib is insoluble in water but dissolves at ≥22.75 mg/mL in DMSO and ≥2.68 mg/mL in ethanol (with gentle warming), facilitating diverse assay formats (APExBIO).

This article extends the discussion in 'Tivozanib (AV-951): Pioneering Functional In Vitro Assessment' by providing quantitative benchmarks and direct clinical trial outcomes, focusing on rigorous, reproducible experimentation.

For additional protocol guidance, see 'Enhancing In Vitro Assays with Tivozanib (AV-951)', which details best practices in assay setup—this article adds recent clinical data and comparative selectivity metrics.

Applications, Limits & Misconceptions

Tivozanib (AV-951) is widely used in oncology research for:

• In vitro modeling of angiogenesis and anti-angiogenic therapy in solid tumor systems.
• Benchmarking selective VEGFR inhibition in cell-based and in vivo xenograft models.
• Combination therapy studies, particularly with EGFR inhibitors, to probe synergistic effects (Schwartz 2022).
• Reference standard for anti-angiogenic drug screening in renal cell carcinoma.

Common Pitfalls or Misconceptions

• Tivozanib is not water soluble: Attempting aqueous preparation results in precipitation; use DMSO or ethanol as solvents (APExBIO).
• Not a broad-spectrum TKI: Tivozanib exhibits minimal activity against kinases outside VEGFR-1/2/3, c-KIT, and PDGFRβ—ineffective for targets such as BCR-ABL or ALK.
• Solutions are not stable long-term: Prepare fresh solutions for each experiment, as storage can reduce activity.
• Clinical dosing does not directly translate to in vitro use: Use ~10 μM for 48 hours in cell assays; do not extrapolate oral dosing to culture systems.
• False synergy with cytotoxics: Synergy is context-dependent and not universal; confirm with proper controls and replicates.

For nuanced discussion of angiogenesis modeling, see 'Tivozanib (AV-951): Precision VEGFR Inhibition in Dynamic Systems', which explores microenvironmental factors—here, we emphasize quantitative performance and selectivity.

Workflow Integration & Parameters

• Compound Preparation: Dissolve Tivozanib at ≥22.75 mg/mL in DMSO or ≥2.68 mg/mL in ethanol (gentle warming if needed).
• Storage: Store dry powder at -20°C; avoid prolonged storage of stock solutions.
• Usage in Cell Assays: Employ 10 μM concentration for 48-hour treatments (typical for viability/apoptosis readouts).
• Combining with Other Agents: For synergy screens, optimize dosing of EGFR or other inhibitors based on cell line sensitivity.
• Assay Controls: Always include vehicle (DMSO) and untreated controls for valid interpretation.
• Data Analysis: Interpret growth and cytotoxicity metrics separately; see fractional vs. relative viability distinction (Schwartz 2022).

For product-specific ordering and batch documentation, refer to the Tivozanib (AV-951) A2251 kit from APExBIO.

Conclusion & Outlook

Tivozanib (AV-951) is a gold-standard tool for dissecting VEGFR-mediated angiogenesis and advancing anti-angiogenic therapy paradigms in oncology research. Its combination of picomolar VEGFR-2 potency, clinical validation in RCC, and minimal off-target profile sets a benchmark for both preclinical and translational studies. For future applications, Tivozanib's role in combination regimens and emerging tumor models warrants continued investigation. Use of rigorously sourced material, such as APExBIO’s A2251, ensures reproducibility and data integrity (Schwartz 2022).